Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng · 2024
Read Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma by Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11663888.txt.
Description
Xiaodan Luo and a large co-author team report, in a 2024 case study, a young man's lasting remission from a hard-to-treat blood cancer. His Burkitt lymphoma had shrugged off several rounds of chemo and immune therapy. The team combined two heavy tools at once.
First came a stem cell transplant using his own cells after strong conditioning. Three days later he received engineered T cells aimed at two targets on the cancer, built with extra signaling parts. At a follow-up past three hundred days, the remission held. He suffered no severe complications from the pairing. One case proves little alone, but it sketches a route for patients out of standard options.
Catalog record
| CREATOR | Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |